Welcome to our dedicated page for JATT news (Ticker: JATT), a resource for investors and traders seeking the latest updates and insights on JATT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JATT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JATT's position in the market.
Zura Bio Limited, a clinical-stage biotechnology company focused on immunology, has completed its business combination with JATT Acquisition Corp. The merger, approved by JATT's shareholders on March 16, 2023, results in approximately $65 million in gross cash proceeds to support R&D initiatives and potential acquisitions. The combined entity will trade under the ticker symbol ZURA on Nasdaq starting March 21, 2023. The funds will be used for the clinical development of Zura's pipeline candidates, ZB-168 and torudokimab, with leadership from former Arena Pharmaceuticals executives. This milestone aims to enhance the company's immunology portfolio.
JATT Acquisition Corp (NYSE: JATT) has received shareholder approval for its business combination with Zura Bio Limited, a clinical-stage biotechnology company. At the extraordinary general meeting, 95.5% of JATT’s outstanding ordinary shares were represented, with 99.9% voting in favor of the merger. The closing is anticipated on March 20, 2023, leading to the trading of new ticker symbols 'ZURA' and 'ZURAW' on the Nasdaq the following day. Zura is developing innovative treatments for conditions such as Alopecia Areata and chronic obstructive pulmonary disease (COPD).
JATT Acquisition Corp (NYSE: JATT) announced its voluntary transfer of listing for its Class A ordinary shares, public warrants, and units from the New York Stock Exchange (NYSE) to the Nasdaq. The shift is in connection with the closing of its business combination with Zura Bio Limited. Trading on NYSE will cease on March 20, 2023, with the new listing on Nasdaq set for March 21, 2023, under the ticker symbols 'ZURA' and 'ZURAW'. This move follows compliance with NYSE’s rules, and the transfer is subject to the closing conditions of the business combination with Zura, a clinical-stage biotechnology firm based in London.
JATT Acquisition Corp (NYSE: JATT) announces that the SEC has declared effective its registration statement on Form S-4 for the proposed business combination with Zura Bio Limited. An extraordinary general meeting is scheduled for March 16, 2023, to seek shareholder approval. Zura Bio, a UK-based biotech firm, focuses on developing innovative treatments for immune and inflammatory diseases. The combination aims to provide Zura with crucial funding to advance its clinical assets, ZB-168 and torudokimab. Following the merger, the new entity will operate as Zura Bio Limited, trading on Nasdaq under the symbols ZURA and ZURAW.
Zura Bio, a biotechnology company, is set to merge with JATT Acquisition Corp (NYSE:JATT) in a transaction valued at approximately
JATT Acquisition Corp (NYSE: JATT U) announces the ability for unit holders to trade ordinary shares and warrants separately starting on September 3, 2021. Each unit consists of one ordinary share and half a warrant, with a whole warrant allowing the purchase of one share at $11.50. Holders will need to have their brokers contact Continental Stock Transfer & Trust Company to separate their units. The ordinary shares and warrants will trade under the symbols JATT and JATT WS, respectively, while unsplit units will remain under JATT U.
FAQ
What is the market cap of JATT (JATT)?
